select a format

Single User License
USD 2000 INR 128200
Site License
USD 4000 INR 256400
Corporate User License
USD 6000 INR 384600

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline Review, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9036IDB
  • |
  • Pages: 63
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline Review, H1 2017, provides an overview of the Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 1, 1, 4 and 1 respectively.

Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).

The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Overview

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Companies Involved in Therapeutics Development

Bionovis SA

Bristol-Myers Squibb Company

ChemoCentryx Inc

Coherus BioSciences Inc

GlaxoSmithKline Plc

Iltoo Pharma

Kyowa Hakko Kirin Co Ltd

Panacea Biotec Ltd

Sandoz International GmbH

The International Biotechnology Center (IBC) Generium

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Drug Profiles

abatacept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aldesleukin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Dormant Projects

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Discontinued Products

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Product Development Milestones

Featured News & Press Releases

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by Bionovis SA, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by Bristol-Myers Squibb Company, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by ChemoCentryx Inc, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by Coherus BioSciences Inc, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by GlaxoSmithKline Plc, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by Iltoo Pharma, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by Panacea Biotec Ltd, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by Sandoz International GmbH, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Pipeline by The International Biotechnology Center (IBC) Generium, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Dormant Projects, H1 2017

Granulomatosis with Polyangiitis (Wegener Polyangiitis)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bionovis SA, Bristol-Myers Squibb Company, ChemoCentryx Inc, Coherus BioSciences Inc, GlaxoSmithKline Plc, Iltoo Pharma, Kyowa Hakko Kirin Co Ltd, Panacea Biotec Ltd, Sandoz International GmbH, The International Biotechnology Center (IBC) Generium

Granulomatosis with Polyangiitis (Wegener Polyangiitis) Therapeutic Products under Development, Key Players in Granulomatosis with Polyangiitis (Wegener Polyangiitis) Therapeutics, Granulomatosis with Polyangiitis (Wegener Polyangiitis) Pipeline Overview, Granulomatosis with Polyangiitis (Wegener Polyangiitis) Pipeline, Granulomatosis with Polyangiitis (Wegener Polyangiitis) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com